218 related articles for article (PubMed ID: 33992061)
21. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
22. Insight γ-Secretase: Structure, Function, and Role in Alzheimer's Disease.
Mal S; Malik U; Pal D; Mishra A
Curr Drug Targets; 2021; 22(12):1376-1403. PubMed ID: 33390127
[TBL] [Abstract][Full Text] [Related]
23. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
[TBL] [Abstract][Full Text] [Related]
24. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
Beher D; Graham SL
Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
[TBL] [Abstract][Full Text] [Related]
25. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
26. Intramembrane proteolysis by gamma-secretase.
Steiner H; Fluhrer R; Haass C
J Biol Chem; 2008 Oct; 283(44):29627-31. PubMed ID: 18650432
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
29. gamma-Secretase as a therapeutic target in Alzheimer's disease.
Guardia-Laguarta C; Pera M; Lleó A
Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
[TBL] [Abstract][Full Text] [Related]
30. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
31. γ-Secretase as a target for Alzheimer's disease.
Wolfe MS
Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
[TBL] [Abstract][Full Text] [Related]
32. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
Imbimbo BP; Giardina GA
Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
[TBL] [Abstract][Full Text] [Related]
33. Substrate-targeting gamma-secretase modulators.
Kukar TL; Ladd TB; Bann MA; Fraering PC; Narlawar R; Maharvi GM; Healy B; Chapman R; Welzel AT; Price RW; Moore B; Rangachari V; Cusack B; Eriksen J; Jansen-West K; Verbeeck C; Yager D; Eckman C; Ye W; Sagi S; Cottrell BA; Torpey J; Rosenberry TL; Fauq A; Wolfe MS; Schmidt B; Walsh DM; Koo EH; Golde TE
Nature; 2008 Jun; 453(7197):925-9. PubMed ID: 18548070
[TBL] [Abstract][Full Text] [Related]
34. Mutations in nicastrin protein differentially affect amyloid beta-peptide production and Notch protein processing.
Pamrén A; Wanngren J; Tjernberg LO; Winblad B; Bhat R; Näslund J; Karlström H
J Biol Chem; 2011 Sep; 286(36):31153-8. PubMed ID: 21768095
[TBL] [Abstract][Full Text] [Related]
35. Activity of gamma-secretase on substrates other than APP.
Lleó A
Curr Top Med Chem; 2008; 8(1):9-16. PubMed ID: 18220928
[TBL] [Abstract][Full Text] [Related]
36. [Development of Alzheimer's disease treatment based on the molecular mechanism of γ-secretase activity].
Tomita T
Rinsho Shinkeigaku; 2012; 52(11):1165-7. PubMed ID: 23196551
[TBL] [Abstract][Full Text] [Related]
37. gamma-Secretase modulators.
Wolfe MS
Curr Alzheimer Res; 2007 Dec; 4(5):571-3. PubMed ID: 18220525
[TBL] [Abstract][Full Text] [Related]
38. Part 1: Notch-sparing γ-secretase inhibitors: The identification of novel naphthyl and benzofuranyl amide analogs.
Lu D; Wei HX; Zhang J; Gu Y; Osenkowski P; Ye W; Selkoe DJ; Wolfe MS; Augelli-Szafran CE
Bioorg Med Chem Lett; 2016 May; 26(9):2129-32. PubMed ID: 27013392
[TBL] [Abstract][Full Text] [Related]
39. First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.
Borgegard T; Juréus A; Olsson F; Rosqvist S; Sabirsh A; Rotticci D; Paulsen K; Klintenberg R; Yan H; Waldman M; Stromberg K; Nord J; Johansson J; Regner A; Parpal S; Malinowsky D; Radesater AC; Li T; Singh R; Eriksson H; Lundkvist J
J Biol Chem; 2012 Apr; 287(15):11810-9. PubMed ID: 22334705
[TBL] [Abstract][Full Text] [Related]
40. Role of presenilin in gamma-secretase cleavage of amyloid precursor protein.
Xia W
Exp Gerontol; 2000 Jul; 35(4):453-60. PubMed ID: 10959033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
